Physician profile
Scott C Boyd
NPI 1386639565
$7,228.40
in general payments reported to CMS, 2019-2025
32 companies · $322 in 2025
The $322 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.24 · 2020: $93.94 · 2021: $3,202 · 2022: $2,168 · 2023: $656 · 2024: $721 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,698.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,004.10 | 2021-2025 | Interstim, Altaviva |
| Axonics, INC. | $2,664.57 | 2021-2024 | Axonics, Bulkamid |
| Boston Scientific Corporation | $215.02 | 2020-2025 | Axonics |
| Sumitomo Pharma America, INC. | $129.36 | 2023-2025 | Gemtesa, Myfembree |
| Abbvie INC. | $112.97 | 2019-2021 | |
| Amgen INC. | $100.54 | 2021-2022 | |
| Caldera Medical, INC | $99.09 | 2021 | |
| Astellas Pharma US INC | $95.48 | 2022-2024 | Veozah |
| Intuitive Surgical, INC. | $82.24 | 2019-2025 | |
| Pfizer INC. | $77.80 | 2022-2023 | |
| Hologic Sales and Service, LLC | $75.60 | 2019-2023 | Acessa Provu System, Coolseal Generator, Myosure Tissue Removal Device |
| Coopersurgical, INC. | $65.15 | 2021-2022 | |
| Urovant Sciences INC | $60.50 | 2021-2022 | |
| Therapeuticsmd, INC. | $51.10 | 2021-2022 | |
| Biogen, INC. | $49.09 | 2024-2025 | Zurzuvae |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $43.48 | 2021-2023 | |
| Myovant Sciences INC. | $40.61 | 2022 | |
| Avion Pharmaceuticals | $39.20 | 2021 | |
| 180 Medical, INC. | $38.86 | 2021-2022 | |
| Channel Medsystems, INC. | $28.40 | 2022 | |
| Coloplast Corp | $23.36 | 2024 | |
| Gynesonics, INC. | $18.64 | 2022 | |
| Mayne Pharma Commercial LLC | $18.00 | 2022 | |
| Daiichi Sankyo INC. | $17.24 | 2023 | Injectafer |
| Ethicon US, LLC | $16.37 | 2021 | |
| Minerva Surgical, INC | $14.37 | 2023 | |
| Exeltis, USA INC. | $13.60 | 2021 | |
| Organon LLC | $11.58 | 2023 | Nexplanon |
| Duchesnay USA Incorporated | $11.29 | 2019 | |
| Medtronic USA, INC. | $10.79 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.